Infezol-40 solution for infusions 500 ml. №10

Description

Infezol-40 Storage
active substances: L-alanine, glycine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-isoleucine, L-lysine hydrochloride, L-methionine, L-leucine, L-phenylalanine, L- threonine, L-tryptophan, L-valine, sodium acetate trihydrate, potassium chloride, magnesium chloride hexahydrate, sodium hydroxide, xylitol;

1 liter of solution for infusion contains: L-alanine 4.00 g; glycine 7.00 g; L-arginine 4.55 g; L-aspartic acid 2.00 g; L-glutamic acid 5.00 g; L-histidine 1.35 g; L-isoleucine 2.10 g; L-lysine hydrochloride 2.50 g (equivalent to 2.00 g of L-lysine); L-methionine 1.75 g; L-leucine 2.75 g; L-phenylalanine 3.15 g; L-threonine 1.60 g; L-tryptophan 0.50 g; L-valine 2.25 g; sodium acetate trihydrate 3.4 g; potassium chloride 1.86 g; magnesium chloride hexahydrate 0.51 g; sodium hydroxide 0.60 g; xylitol 50.00 g;

Excipients:

sodium disulfite, water for injections.

Infezol-40 Dosage form
Solution for infusion.

Basic physical and chemical properties: transparent, almost colorless or with a yellowish tinge liquid. Theoretical osmolarity: 801.8 mOsm / l; pH: 5.7–7.0; total energy value – 1551.0 kJ / l; total nitrogen content – 6.3 g

Infezol-40 Pharmacotherapeutic group
Means for parenteral nutrition. ATX code B05B A10.

Pharmacological properties

Pharmacodynamics.

Amino acids, carbohydrates and electrolytes are physiological substances or metabolic analogues.

Amino acids administered intravenously serve as links for protein synthesis. Xylitol is an energy carrier that is broken down in the process of carbohydrate metabolism at the level of the liver, and its metabolites enter the processes of glycolysis and gluconeogenesis.

Pharmacokinetics.

When infused, the bioavailability of the drug Infezol® 40 is 100%.

Amino acids are fully used for protein synthesis. Excess amino acids that are not needed for the synthesis of proteins and other biomolecules do not accumulate in the body like fatty acids and glucose. Only 5% of amino acids are excreted unchanged. The breakdown of amino acids occurs by deamination of the α-amino group, which is converted into urea, which is excreted by the kidneys. The remaining carbohydrate skeleton is included in the citric acid cycle, where it is converted into acetyl-Co-A, acetone acetyl-Co-A, pyruvate or an intermediate.

Indication
Parenteral nutrition for the prevention and treatment of protein loss and to provide fluid, for example, after surgery, bleeding, burns. Replenishment or elimination of protein deficiency that occurs due to increased need for it, increased costs or due to disruption of protein intake during digestion, absorption and excretion.

Contraindication
Severe liver damage, impaired amino acid metabolism (phenylketonuria), traumatic brain injury, hyperhydration, methanol intoxication, hypersensitivity to one of the amino acids or to sodium disulfite. Hyperkalemia, shock, hypoxia, metabolic acidosis, severe renal insufficiency (in the absence of sufficient diuresis), pathologically high plasma levels of one of the electrolytes contained in the drug. Decompensated heart failure, acute pulmonary edema. Children under 2 years old.

Special security measures
Use only clear solutions in undamaged vials.